Xie Feihu, Sun Lejia, Pang Yuan, Xu Gang, Jin Bao, Xu Haifeng, Lu Xin, Xu Yiyao, Du Shunda, Wang Yanan, Feng Shi, Sang Xinting, Zhong Shouxian, Wang Xin, Sun Wei, Zhao Haitao, Zhang Hongbing, Yang Huayu, Huang Pengyu, Mao Yilei
Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences (CAMS), Beijing, 100730, China.
Biomanufacturing Center, Department of Mechanical Engineering, Tsinghua University, Beijing, 100084, China; Biomanufacturing and Rapid Forming Technology Key Laboratory of Beijing, Beijing, 100084, China; Overseas Expertise Introduction Center for Discipline Innovation, Tsinghua University, Beijing, 100084, China.
Biomaterials. 2021 Jan;265:120416. doi: 10.1016/j.biomaterials.2020.120416. Epub 2020 Sep 22.
Hepatocellular carcinoma (HCC) is one of the most lethal tumors worldwide. This study aims to address the lack of faithful and available in vitro models for patient-specific drug screening for HCC. We recently established a novel modeling system using three-dimensional (3D) bioprinting technology and constructed hepatorganoids with HepaRG cells, which retain the liver function and prolong the survival of mice with liver failure after abdominal transplantation. Here we extend this modeling system to establish individualized model for hepatocellular carcinoma. HCC specimens were obtained from six patients after surgery. Primary HCC cells were isolated and mixed with gelatin and sodium alginate to form the bioink for printing. Patient-derived three-dimensional bio-printed HCC (3DP-HCC) models were successfully established afterward and grew well during long-term culture. These models retained the features of parental HCCs, including stable expression of the biomarker, stable maintenances of the genetic alterations and expression profiles. 3DP-HCC models are capable of displaying the results of drug screening intuitively and quantitatively. In conclusion, 3DP-HCC models are faithful in vitro models that are reliable in long-term culture and able to predict patient-specific drugs for personalized treatment.
肝细胞癌(HCC)是全球最致命的肿瘤之一。本研究旨在解决缺乏用于HCC患者特异性药物筛选的可靠且实用的体外模型这一问题。我们最近利用三维(3D)生物打印技术建立了一种新型建模系统,并用HepaRG细胞构建了肝类器官,这些肝类器官保留了肝功能,并延长了腹部移植后肝功能衰竭小鼠的生存期。在此,我们扩展该建模系统以建立肝细胞癌的个体化模型。术后从6例患者获取HCC标本。分离出原发性HCC细胞,并与明胶和海藻酸钠混合以形成用于打印的生物墨水。随后成功建立了患者来源的三维生物打印HCC(3DP - HCC)模型,且在长期培养过程中生长良好。这些模型保留了亲代HCC的特征,包括生物标志物的稳定表达、基因改变和表达谱的稳定维持。3DP - HCC模型能够直观且定量地展示药物筛选结果。总之,3DP - HCC模型是可靠的体外模型,在长期培养中稳定,能够预测用于个性化治疗的患者特异性药物。